Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.
There is limited published data at higher doses and none in the treatment of Major Depressive Disorder (MDD). Methods This open-label, pilot study was designed to investigate the efficacy ...
Major depressive disorder (MDD) is a leading cause of disability worldwide and unfortunately no treatment without side effects is available. Previous reports have found unbalanced glutamate-glutamine ...
Each person's response to each medicine may vary. According to a systematic review of several studies, both medications are effective for the short-term treatment of major depressive disorder. Another ...